For identification of suitable strategies to target melanoma, effects of the BRAF inhibitor vemurafenib (10, 20, 30 μM), the pERK inhibitor SCH772984 (0.1, 1, 10 μM), and the Mcl-1 inhibitor S63845 (0.25, 0.5, 1 μM) were investigated in BRAF-mutated melanoma cell lines (A-375 and Mel-HO), as well as in BRAF-WT cell lines (MeWo and SK-Mel-23). This evidence concerns the gene MCL1 and melanoma.